Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HLX105
- Development stage
- Preclinical
- Lead developer
- Henlius
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
HLX105 is an early-stage recombinant fusion protein being developed by Shanghai Henlius Biotech, Inc. As part of Henlius's expanding pipeline of innovative biologics, HLX105 is currently in the preclinical or early clinical phase of development. While the company has identified the molecule as a fusion protein, specific details regarding its biological target, mechanism of action, and primary therapeutic indications have not been publicly disclosed as of mid-2024. The development of HLX105 reflects Henlius's strategy to move beyond biosimilars into novel therapeutic modalities, potentially targeting oncology or inflammatory diseases.
Beyond the preview
Go deeper on HLX105.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HLX105.